Enjoy complimentary customisation on priority with our Enterprise License!
The addictions therapeutics market size is forecast to increase by USD 10.8 billion at a CAGR of 7.83% between 2023 and 2028. The market is driven by various factors, including the widespread consumption of alcohol, tobacco, and opioid products globally. With the approval of new drugs and the introduction of digital therapeutics, there is a growing arsenal of treatments available to combat addiction. Additionally, initiatives aimed at increasing awareness and addressing addiction are contributing to the market's growth, offering hope for individuals struggling with substance abuse disorders. It also includes an in-depth analysis of market trends and analysis, market growth analysis and challenges. Furthermore, the report includes historic market data from 2018 - 2022.
To learn more about this report, View Report Sample
The market encompasses a range of substances and treatments used to address various addictive disorders. These disorders can include substance addictions, such as those to alcohol, drugs, or nicotine, as well as behavioral addictions, like gambling or internet use. The market includes a diverse array of pharmaceutical interventions, such as methadone and buprenorphine for opioid addiction, and acamprosate and disulfiram for alcohol use disorders. Additionally, behavioral therapies, like cognitive-behavioral therapy, addiction therapeutics and contingency management, are commonly used in the treatment of addictions. The market for addictions therapeutics is driven by the growing prevalence of addictive disorders worldwide, as well as increasing awareness and acceptance of the need for effective treatment. The market landscape depends on the Alcoholic beverage sales, wine sales, beer sales, spirits sales, ciders and coolers sales. The use of subsidies and insurance coverage for addiction treatment is also a significant factor in market growth. The market for addictions therapeutics is expected to continue expanding in the coming years, as new treatments and interventions are developed and the stigma surrounding addiction continues to decrease.. Our researchers studied the data for years, with 2023 as the base year, and 2024 as the estimated year, and presented the key drivers, trends, and challenges for the market.
One of the key factors driving growth in the market is the high consumption of alcohol, tobacco, and opioid products. The high consumption of alcohol, tobacco, and opioids globally drives the growth of the market. Despite increasing awareness about and stringent regulations on the consumption of these products, the market has witnessed an increase in the consumption of alcohol, opioids, and tobacco products. Opioids are a type of narcotic pain medication that is available as a therapy for the treatment of moderate-to-severe pain in many developed countries.
However, the misuse and abuse of opioids lead to opioid tolerance and addiction. The high consumption of alcohol, tobacco, and opioid products on a daily basis can lead to a strong desire or sense of compulsion to consume the substance. This results in complications in controlling substance use behavior in terms of its onset, termination, and levels of use, which leads to substance use disorder, also known as substance dependency. Owing to the high consumption of these substances, the prevalence of substance use disorders has increased globally. Hence, the high consumption of these substances increases the prevalence of addiction globally, thereby driving market growth.
The increasing R&D of novel drugs is another factor supporting the market share growth in coming years. Due to the increasing consumption of alcohol, tobacco, and opioid products, the demand for novel therapeutics to treat substance use disorders has increased. Therefore, several companies are focusing on the development of novel therapeutics to treat substance use disorders.
Opiant Pharmaceuticals is developing OPNT002, nasal naltrexone, which produces rapid and strong increases in the plasma level and blocks the opioid receptor. As per the studies, OPNT002 offers some significant advantages over current treatment options by addressing the challenges faced by alcohol use disorder patients.
Adial Pharmaceutical is developing AD04 (ondansetron), a genetically targeted therapeutic agent for alcohol use disorder. AD04 can be used to treat other addictive disorders, such as opioid use disorder, obesity, and smoking MediciNova is developing MN-166 (ibudilast) to treat methamphetamine addiction. The company has completed a Phase II study of MN-166 for methamphetamine dependence. Amygdala Neurosciences is also developing ANS-6637, an oral aldehyde dehydrogenase 2 inhibitor. The drug modifies dopaminergic tone in the brain by preventing abnormal dopamine surges that drive craving without changing basal dopamine levels. The strong R&D and pipeline of addiction therapeutics are expected to drive the growth of the global market during the forecast period.
The presence of generics will be a major challenge for the market during the forecast period. The presence of generic drugs impacts the market, as the price of generic drugs is almost half the price of branded drugs. With an increase in the number of ANDA approvals, more generic drug manufacturers have entered the market, which is intensifying the competition in the market. The competition among generic drug makers is based on the low prices of generic drugs. The entry of generic drugs into the market leads to price wars that reduce drug prices. This impacts the overall market growth, as a reduction in drug prices leads to less revenue generation in the market.
The global market has the presence of branded and generic drug manufacturers. Owing to the loss of patents, many generic drug manufacturers, such as Cipla, Mylan, Teva Pharmaceutical, and InnoPharma Inc., have received generic drug approvals from the US FDA to market generic drugs such as acamprosate calcium. Since several generic manufacturers have entered the market, generic drugs have become more affordable than branded drugs. Thus, patent expiry and the growing penetration of generic drugs may impede the growth of the global market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.
Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Alkermes Public Ltd. Co: The company offers addictions therapeutic named Vivitrol, an injectable which is prescribed to take once-monthly, and is an extended-release form of naltrexone, an opioid receptor antagonist.
The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
In the distribution channel segment of the market, a multifaceted approach is adopted to address the diverse needs of individuals grappling with substance abuse disorders. Traditional channels such as medical stores play a pivotal role in providing access to medications targeting addictive substances, including synthetic drugs and new psychoactive substances. Moreover, rehabilitation facilities serve as essential outlets for comprehensive treatment, offering both medicinal and psychotherapeutic interventions. With the advent of telehealth services, individuals can access addiction treatment remotely, ensuring the widespread availability of support services. Innovative therapy adoption, driven by neuroscientific advances and technological advancements in diagnostics, is reshaping the landscape of addiction treatment. Additionally, collaborations between pharmaceutical companies and healthcare providers foster the development of novel therapies and enhance the efficacy of existing treatments. The legalization of marijuana prompts heightened drug awareness campaigns, emphasizing the importance of early intervention and treatment. Insights from organizations like Statistics Canada shed light on alcohol consumption patterns, guiding the allocation of resources and healthcare expenditure towards addiction treatment initiatives. Despite challenges such as alcohol cravings, insomnia, anxiety, and restlessness, concerted efforts across various distribution channels aim to mitigate the impact of substance abuse disorders and promote holistic recovery.
The market share growth by the hospital pharmacy segment will be significant during the forecast period. Hospital pharmacy is an important distribution channel for the global market. The hospital pharmacy segment accounts for a significant share of the market, owing to a wider range of facilities and advanced infrastructure to cater to the different needs of patients. These factors will positively impact the growth of the hospital pharmacy segment of the global market during the forecast period.
Get a glance at the market contribution of various segments View the PDF Sample
The hospital pharmacy segment was valued at USD 6.50 billion in 2018. Owing to the good discounts, improving reimbursement, and the growing number of drug addicts, hospital pharmacies experience increasing demand. Hospital groups or multi-specialty or super-speciality hospitals play an important role in terms of sales in this market. These hospitals are benefitted due to the availability of extensive inpatient and outpatient services, which help them generate high revenue. Owing to the good discounts, improving reimbursement, and the growing number of drug addicts, hospital pharmacies experience increasing demand. These factors will positively impact the growth of the hospital pharmacy segment of the global market during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The market in North America is significant due to the high prevalence of substance use disorders, particularly with amphetamines, alcohol, opioids, tobacco, marijuana, and cocaine. Mental disorders increase the likelihood of addiction to these substances and behaviors. Addicted individuals experience compulsive drug seeking, leading to harmful consequences. Drug treatment is essential for managing addiction, which can be a chronic disorder with occasional relapses. Alcohol use disorder and opioid addiction are common, while tobacco use and passive smoke exposure also contribute. Rehabilitation programs offer various treatments in different settings, including short-term and long-term processes, multiple interventions, and regular monitoring to prevent drug overdosing. Americans struggle with marijuana use and cocaine use, among other substances. Treatment is a long-term process requiring ongoing care and support for patients. Hence, such factors are driving the market in North America during the forecast period.
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The market encompasses a range of treatments designed to address substance and behavioral addictions. These therapeutics include Alcoholics Anonymous (AA) and other support groups, pharmacotherapies such as Acamprosate, Naltrexone, and Disulfiram, as well as Cognitive-Behavioral Therapies (CBT), Motivational Enhancement Therapy (MET), and other psychotherapies. The market for these therapeutics is significant, with a growing recognition of the need for effective interventions to address the global burden of addiction. The Substance Abuse and Mental Health Services Administration (SAMHSA) reports that in the US alone, over 20 million adults struggle with substance abuse or addiction. The market for Addictions Therapeutics is expected to grow, driven by increasing awareness, research, and development efforts, as well as the expanding global population and rising healthcare costs. The use of technology, such as telehealth and mobile applications, is also expected to play a role in expanding access to these important therapeutics.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
173 |
|
Base year |
2023 |
|
Historic period |
2018 - 2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 7.83% |
|
Market growth 2024-2028 |
USD 10.8 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
7.2 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 46% |
|
Key countries |
US, Germany, UK, Canada, and France |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Alkermes Public Ltd. Co., Amneal Pharmaceuticals Inc., Aphios Corp., Braeburn Inc., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc, Indivior Plc, Johnson and Johnson Services Inc., kaleo Inc., Mallinckrodt Plc, Orexo AB, Otsuka Holdings Co. Ltd., Pfizer Inc., Purdue Pharma LP, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Titan Pharmaceuticals Inc., and Viatris Inc. |
|
Market dynamics |
Parent market analysis, Market forecast, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.